| S&P500 and Nasdaq Index: Consumer Data Sinks Sentiment, Super Micro, Moderna Rally |
S&P 500 and Nasdaq edge higher mid-session as weak sentiment data tempers gains. Traders assess inflation risks and tariff uncertainty. |
fxempire.com |
2025-05-16 16:00:13 |
Czytaj oryginał (ang.) |
| 1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid |
Equity markets are full of bargains -- stocks that have performed terribly in recent months, whether due to trade-related marketwide issues or company-specific troubles, but could bounce back once things improve. There are also companies that are not performing well and are unlikely to rebound anytime soon; that's the kind investors should stay away from. |
fool.com |
2025-05-16 09:30:00 |
Czytaj oryginał (ang.) |
| Cautious? Risky? Our Volatility Scorecard Can Help |
Subscribers to Chart of the Week received this commentary on Sunday, May 11. |
schaeffersresearch.com |
2025-05-13 15:08:35 |
Czytaj oryginał (ang.) |
| Why Moderna Merged Its Tech and HR Departments |
The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech. |
wsj.com |
2025-05-12 11:00:00 |
Czytaj oryginał (ang.) |
| Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 |
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decisions Conference (SDC), on Thursday, May 29th at 10:00am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com. |
accessnewswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| New vaccine chief rocks pharmaceutical stocks |
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump. |
youtube.com |
2025-05-07 15:13:02 |
Czytaj oryginał (ang.) |
| Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1 |
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales. |
zacks.com |
2025-05-06 14:55:38 |
Czytaj oryginał (ang.) |
| Moderna faces long-term threat from NIH's universal vaccine initiative, Jefferies says |
Moderna Inc (NASDAQ:MRNA, ETR:0QF) could face a longer-term threat from a newly announced US government initiative to develop universal vaccines for pandemic-prone viruses, analysts at Jefferies said on Friday. The National Institutes of Health (NIH) unveiled plans this week to build a next-generation vaccine platform aimed at creating broad-spectrum, long-lasting protection against viruses like avian flu and coronaviruses. |
proactiveinvestors.com |
2025-05-02 17:53:50 |
Czytaj oryginał (ang.) |
| Moderna (MRNA) Reports Q1 Earnings: What Key Metrics Have to Say |
The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-02 14:35:55 |
Czytaj oryginał (ang.) |
| Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell |
Moderna's Q1 earnings reveal a significant revenue decline and high cash burn, driven by reduced demand for its COVID-19 vaccine and inventory write-downs. Regulatory setbacks for Moderna's combination flu/COVID-19 vaccine delay its market entry, adding to the company's challenges amid strong competition from other drugmakers. Despite cost-cutting efforts, Moderna's financial health is strained, with high costs and low margins, leading to a downgrade to "Sell" or "market underperform." |
seekingalpha.com |
2025-05-01 17:30:12 |
Czytaj oryginał (ang.) |
| Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026 |
Moderna Inc. MRNA reported on Thursday a first-quarter EPS loss of $(2.52), missing the consensus of $(3.12), down from an EPS loss of $(3.07) a year ago. |
benzinga.com |
2025-05-01 17:14:38 |
Czytaj oryginał (ang.) |
| Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts |
MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027. |
zacks.com |
2025-05-01 16:26:05 |
Czytaj oryginał (ang.) |
| Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript |
Moderna, Inc. (NASDAQ:MRNA ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Salveen Richter - Goldman Sachs Tyler Van Buren - TD Cowen Cory Kasimov - Evercore ISI Courtney Breen - Bernstein Dick Gottfred - William Blair Gena Wang - Barclays Operator Good day, and thank you for standing by. Welcome to the Moderna First Quarter 2025 Conference Call. |
seekingalpha.com |
2025-05-01 16:01:41 |
Czytaj oryginał (ang.) |
| Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates |
Moderna (MRNA) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $2.92. This compares to loss of $3.07 per share a year ago. |
zacks.com |
2025-05-01 12:40:22 |
Czytaj oryginał (ang.) |
| Moderna Posts Loss, Citing Seasonality of Respiratory Business |
Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year. |
wsj.com |
2025-05-01 10:38:00 |
Czytaj oryginał (ang.) |
| Moderna beats Wall Street estimates for first-quarter profit and sales |
Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine. |
reuters.com |
2025-05-01 10:33:58 |
Czytaj oryginał (ang.) |
| Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates |
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billion Announces reduction of $1.4 to $1.7 billion in estimated GAAP operating costs by 2027 Advancing up to 10 products toward approval, including multiple oncology candidates CAMBRIDGE, MA / ACCESS Newswire / May 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2025. "In the first quarter, we continued to execute with financial discipline, significantly reducing our operating expenses, and further prioritized our investments in oncology," said Stéphane Bancel, Chief Executive Officer of Moderna. |
accessnewswire.com |
2025-05-01 10:30:00 |
Czytaj oryginał (ang.) |
| Moderna Earnings Arrive During a Tough Time for the Stock |
Moderna shares are down more than 30% this year, and around 75% over the past 12 months. |
barrons.com |
2025-04-30 20:38:00 |
Czytaj oryginał (ang.) |
| CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting |
Novel engineering approach to developing an mRNA-encoded masked IL-12 therapeutic demonstrates potent anti-tumor activity with significantly enhanced tolerability Novel engineering approach to developing an mRNA-encoded masked IL-12 therapeutic demonstrates potent anti-tumor activity with significantly enhanced tolerability |
globenewswire.com |
2025-04-28 20:00:00 |
Czytaj oryginał (ang.) |
| Countdown to Moderna (MRNA) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS |
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025. |
zacks.com |
2025-04-28 14:21:11 |
Czytaj oryginał (ang.) |
| Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds |
Moderna stock toppled Thursday on reports the Trump administration is considering pulling bird flu vaccine funding. The post Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds appeared first on Investor's Business Daily. |
investors.com |
2025-02-27 16:30:37 |
Czytaj oryginał (ang.) |
| Moderna's stock stumbles on report HHS is reviewing a $590 million bird-flu-vaccine award |
The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration. |
marketwatch.com |
2025-02-27 13:08:00 |
Czytaj oryginał (ang.) |
| Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock? |
Moderna (MRNA -6.67%) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future. But you may be surprised to learn that now you can buy the stock around the levels it was at in April 2020 -- even before regulators approved its vaccine. |
fool.com |
2025-02-27 12:05:00 |
Czytaj oryginał (ang.) |
| FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled |
A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month. |
forbes.com |
2025-02-27 04:53:56 |
Czytaj oryginał (ang.) |
| Trump administration weighs pulling funding for Moderna bird flu vaccine, Bloomberg News reports |
U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources. |
reuters.com |
2025-02-26 21:38:00 |
Czytaj oryginał (ang.) |
| SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate |
SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026 Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI SK bioscience will expand its vaccine portfolio and secure global competitiveness by developing mRNA vaccines SEONGNAM, South Korea , Feb. 25, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced the commencement of global Phase 1/2 clinical trials for its mRNA-based Japanese encephalitis vaccine candidate, GBP560. SK bioscience's development of vaccine for Japanese encephalitis could not only help to protect against Japanese Encephalitis but also pave the way to the development of an mRNA technology that could be potentially adapted in a matter of weeks to develop a vaccine against a novel as-yet-identified infectious disease 'Disease X'. |
prnewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| Moderna to Present at Upcoming Conferences in March 2025 |
CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, on Wednesday, March 5th at 9:10am ET Barclays 27th Annual Global Healthcare Conference, on Tuesday, March 11th at 1:30pm ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast: investors.modernatx.com. |
accessnewswire.com |
2025-02-25 09:00:00 |
Czytaj oryginał (ang.) |
| CancerVax Announces Successful Tests of its Smart mRNA Technology |
Recent in-vitro lab results confirm that the Company's proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells Recent in-vitro lab results confirm that the Company's proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells |
globenewswire.com |
2025-02-25 05:01:00 |
Czytaj oryginał (ang.) |
| Moderna (MRNA) International Revenue Performance Explored |
Explore how Moderna's (MRNA) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects. |
zacks.com |
2025-02-24 12:15:32 |
Czytaj oryginał (ang.) |
| Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus |
Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic. |
zacks.com |
2025-02-24 11:30:27 |
Czytaj oryginał (ang.) |
| Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China |
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday. |
investopedia.com |
2025-02-21 20:05:49 |
Czytaj oryginał (ang.) |
| Moderna and Other Vaccine Stocks Climb After Coronavirus News From China |
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday. |
investopedia.com |
2025-02-21 19:30:52 |
Czytaj oryginał (ang.) |
| 3 Biotech/Healthcare Names Under $10 I Am Buying Now |
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects. |
seekingalpha.com |
2025-02-21 18:21:52 |
Czytaj oryginał (ang.) |
| Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. |
In the dark days of the coronavirus pandemic, Moderna (MRNA 0.42%) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to market, not only protecting hundreds of millions of people from COVID-19, but also producing gobs of revenue and healthy profits. |
fool.com |
2025-02-20 05:22:00 |
Czytaj oryginał (ang.) |
| Moderna: A Generational Opportunity for Investors in 2025 |
As bad as it may look on the charts, Moderna's NASDAQ: MRNA post-COVID let-down and market reset are over. The company stock trades at rock bottom in early 2025 and presents a generational opportunity in cutting-edge biotech. |
marketbeat.com |
2025-02-19 09:53:01 |
Czytaj oryginał (ang.) |
| Moderna shares move higher as investors look beyond Q4 losses to pipeline potential |
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares added more than 8% during Tuesday's session as investors remained optimistic about the company's long-term strategy following mixed fourth quarter earnings. The company last week reported a wider-than-expected loss for Q4, as revenue surpassed expectations. |
proactiveinvestors.com |
2025-02-18 16:57:26 |
Czytaj oryginał (ang.) |
| Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges |
On Friday, Moderna Inc. MRNA reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from EPS income of $0.55 a year ago. |
benzinga.com |
2025-02-18 15:44:22 |
Czytaj oryginał (ang.) |
| Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release? |
Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA stock. |
zacks.com |
2025-02-18 12:16:16 |
Czytaj oryginał (ang.) |
| A lot of concern around Moderna over next year or so, says Jefferies Michael Yee |
Michael Yee, Jefferies senior analyst, joins 'Closing Bell Overtime' to talk Moderna Q4 results. |
youtube.com |
2025-02-14 19:07:38 |
Czytaj oryginał (ang.) |
| Moderna (MRNA) Rises But Trails Market: What Investors Should Know |
In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day. |
zacks.com |
2025-01-03 21:11:59 |
Czytaj oryginał (ang.) |
| Moderna: From Breakthrough COVID-19 Vaccines To Personalized Cancer Therapies |
Moderna's partnership with Merck in personalized cancer therapies and promising Phase III trials support a speculative 'Buy' for long-term investors with high-risk tolerance. Despite a tough 2024, MRNA's pipeline reprioritization and $9 billion cash reserve position it for potential blockbuster products and revenue growth by 2028. Financial discipline has reduced cash burn and extended runway, with upcoming Phase III results in oncology and CMV expected to drive future profitability. |
seekingalpha.com |
2025-01-03 05:29:16 |
Czytaj oryginał (ang.) |
| Can The 3 Worst S&P 500 Stocks in 2024 Bounce Back in 2025? |
Of the 503 stocks in the S&P 500 (some companies have two classes of stocks that are included) fewer than 30% of them, or 148 stocks, beat the index's average return of 23.31% in 2024. |
247wallst.com |
2025-01-02 12:28:56 |
Czytaj oryginał (ang.) |
| Moderna: 2025 Contrarian Play |
Moderna ends 2024 as one of the worst-performing Nasdaq-100 stocks, but it presents a contrarian play for 2025 due to vaccine catalysts. The stock is down to $40 with a $15 billion market cap, despite having $3+ billion in revenue and a promising pipeline. Moderna's spending issue is a concern, but the potential of its CMV and cancer vaccines could significantly boost sales and justify current R&D expenses. |
seekingalpha.com |
2024-12-31 14:46:00 |
Czytaj oryginał (ang.) |
| Wall Street's top 5 stocks with the biggest upside in 2025 |
As 2024 is nearing its end, investors with a time machine are looking to visit December 2023 and take their long positions in Nvidia (NASDAQ: NVDA), Tesla (NASDAQ: TSLA), Super Micro Computer (NASDAQ: SMCI) – though with a sell order placed for April – and myriad Chinese stocks, again, with a sell order for October 1. |
finbold.com |
2024-12-26 08:15:00 |
Czytaj oryginał (ang.) |
| mRNA Vaccines and Therapeutics Market Expected to Reach USD 253.83 Billion By 2034, With 16.7% CAGR From 2025 to 2034 | PMR |
The global market for mRNA vaccines and therapeutics is expanding due to the rising incidence of chronic illnesses worldwide. The global market for mRNA vaccines and therapeutics is expanding due to the rising incidence of chronic illnesses worldwide. |
globenewswire.com |
2024-12-26 04:00:00 |
Czytaj oryginał (ang.) |
| Moderna Stock Down 39% in Three Months: Buy the Dip or Wait? |
Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028. |
zacks.com |
2024-12-23 11:05:18 |
Czytaj oryginał (ang.) |
| Is Moderna Stock a Buy? |
Moderna's (MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock price have been moving in the wrong direction for the past three years, a period during which the biotech has lost 85% of its value. |
fool.com |
2024-12-20 08:45:00 |
Czytaj oryginał (ang.) |
| 3 Stocks That Could Turn $1,000 into $5,000 by 2030 |
A five-bagger in only five years? Any investor would love to buy such a stock. |
fool.com |
2024-12-20 06:50:00 |
Czytaj oryginał (ang.) |
| This Feels Like the Post-Pandemic Rally. 3 Stocks to Buy If It Is |
The incredible returns equity investors have seen in 2024, and over the past couple months for that matter, have been incredible. |
247wallst.com |
2024-12-18 13:13:57 |
Czytaj oryginał (ang.) |
| 3 No-Brainer Biotech Stocks to Buy With $200 Right Now |
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs. |
fool.com |
2024-12-18 07:44:00 |
Czytaj oryginał (ang.) |
| 3-Stock Lunch: Palantir, MicroStrategy and Moderna |
Steve Grasso, Grasso Global CEO, joins 'Power Lunch' to discuss stock plays for three stocks. |
youtube.com |
2024-12-16 17:30:54 |
Czytaj oryginał (ang.) |
| MSTR & PLTR Joins the NDX, SMCI & MRNA Exit |
New names will join the Nasdaq-100. Microstrategy (MSTR) and Palantir (PLTR) will enter the index alongside Axon Enterprise (AXON) later this month. |
youtube.com |
2024-12-16 12:03:02 |
Czytaj oryginał (ang.) |
| Palantir, MicroStrategy Could Be Added to Nasdaq 100 Friday. Moderna, Super Micro Could Be Dropped. |
The Nasdaq is due to announce any changes to the Nasdaq 100 index as part of its annual reconstitution at 8 p.m. ET Friday. |
barrons.com |
2024-12-13 13:46:00 |
Czytaj oryginał (ang.) |
| SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate |
SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials in Australia in February 2025, with interim results expected by 2026. Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. |
prnewswire.com |
2024-12-12 10:00:00 |
Czytaj oryginał (ang.) |
| These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over |
2024 has been a generally outstanding year for the stock market, with the S&P 500 (^GSPC 0.82%) up by nearly 30% year to date as of Dec. 11. However, not all stocks have performed nearly this well –- in fact, some components of the S&P 500 have underperformed the benchmark index by as much as 90 percentage points. |
fool.com |
2024-12-12 09:03:00 |
Czytaj oryginał (ang.) |
| Analysts Predict These Will Be Next Year's Top 10 Stocks |
Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025. |
investors.com |
2024-12-11 10:00:52 |
Czytaj oryginał (ang.) |
| mRNA Vaccines and Therapeutics Industry Forecast to Generate Over $72 Billion in Revenues by 2032 - Breakdown by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-user, and Region |
Growing Incidence of Chronic and Infectious Diseases, Advancements in Synthetic Biology & Bioinformatics, Rising Demand for Personalized Medicine Growing Incidence of Chronic and Infectious Diseases, Advancements in Synthetic Biology & Bioinformatics, Rising Demand for Personalized Medicine |
globenewswire.com |
2024-12-11 06:18:00 |
Czytaj oryginał (ang.) |
| Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline |
Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced by 34% PHILADELPHIA , Dec. 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to focus its resources on advancing its in vivo macrophage engineering platform for the development of fibrosis, oncology and autoimmune disease therapies. |
prnewswire.com |
2024-12-09 10:30:00 |
Czytaj oryginał (ang.) |
| mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider |
Strong demand for mRNA-based vaccines and therapies continues to fuel market growth in diverse therapeutic areas, including oncology, infectious diseases, and rare genetic disorders. Strong demand for mRNA-based vaccines and therapies continues to fuel market growth in diverse therapeutic areas, including oncology, infectious diseases, and rare genetic disorders. |
globenewswire.com |
2024-12-08 10:00:00 |
Czytaj oryginał (ang.) |